Source: MS Money Moves July 8th-12th the Healthcare sector underperformed the greater markets as evident by the XLV and the IBB closing down -.66% and -2.06%, respectfully. The XBI stayed … [Read more...] about Biopharma Stock Watch July 15th-19th
Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Calithera Bio-sciences (Nasdaq: CALA) looks to have established a double bottom. New strong uptrend suggests it … [Read more...] about CALITHERA Initiates & Potential Buying Opportunity
EYPT | Range bound by follow_the_money on TradingView.com Long-Term pattern suggests that after previous dilution, Eyepoint Pharmaceuticals (Nasdaq: EYPT) stock price went range bound for quite … [Read more...] about Eyepoint’s Range Bound, Swing Opportunity?
ESG has been a hot topic amongst the investment community recently. As climate catastrophe looms closer and closer, millennials mature and demand more from corporations and other factors continue to … [Read more...] about Mutual Fund LDVAX Booked 37%+ Returns, Is It Still A Buy?
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Source: MS Money Moves Overall it was a red week for biotech whereas the greater market (S&P, NASDAQ, and DOW) gained a little under +1% each. In the past 30-days the healthcare sector … [Read more...] about Biopharma Stock Watch July 8th-12
Tumor-agnostic therapy is the idea that a molecular or genetic alteration in a tumor can be targeted by a therapy, regardless of the tumors location in the body (link). This requires that the tumor be … [Read more...] about Tumor-Agnostic Therapy: LOXO…Array…Now Who?
While writing my weekly Biopharma Stock Watch article for our members, I stumbled across an exciting clinical-stage gene therapy company Krystal Biotech (Nasdaq: KRYS). Since we started following KRYS … [Read more...] about Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th